Postoperative Steroid Use in Adolescent Idiopathic Scoliosis and Neuromuscular Scoliosis Patients
NCT06023043
Not Yet Recruiting
The goal of this randomized clinical trial is to compare the immediate use of steroids after surgery for accelerated discharge in adolescent idiopathic scoliosis and neuromuscular scoliosis after a posterior spinal fusion. The main question it aims to answer are: * What are the effects of using steroids immediately after surgery in decreasing opioid use and helping early mobilization(movement)? * Does post-operative steroid use affect the incidence of wound complications and are there any long... Read More
Gender:
ALL
Ages:
Between 9 years and 18 years
Trial Updated:
03/03/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Neuromuscular Scoliosis, Adolescent Idiopathic Scoliosis
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05259839
Recruiting
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: University of Arkansas for Medical Sciences /ID# 243096, Little Rock, Arkansas +48 locations
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
NCT05486481
Withdrawn
This phase I/II trial tests the safety, side effects, and best dose of venetoclax, daratumumab, and dexamethasone for the treatment of systemic light-chain amyloidosis in patients with a deoxyribonucleic acid (DNA) abnormality called a translocation involving chromosomes 11 and 14, or "t(11;14)". Venetoclax works by attaching to a protein called Bcl-2, in order to kill cancer cells. Daratumumab works by binding to a target on the surface of cancer cells called Cluster of differentiation 38 (CD38... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease
Register for Updates
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
NCT06616597
Recruiting
To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Prostate Cancer (Adenocarcinoma), Metastatic Prostate Cancer
Register for Updates
To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT03544281
Completed
This study will evaluate the safety and tolerability profile of belantamab mafodotin when administered in combination with approved regimens of either Lenalidomide Plus Dexamethasone \[Len/Dex (Treatment A)\] or Bortezomib Plus Dexamethasone \[Bor/Dex (Treatment B)\] in participants with RRMM, i.e., those who have relapsed or who are refractory to at least 1 line of approved therapy. Participants receiving treatment A, may continue combination treatment until the occurrence of progressive disea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: GSK Investigational Site, Birmingham, Alabama +25 locations
Conditions: Multiple Myeloma
Register for Updates
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03914625
Active Not Recruiting
This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as vincristine, dexamethasone, prednisone, prednisolone, pegaspargase, methotrexa... Read More
Gender:
ALL
Ages:
Between 365 days and 31 years
Trial Updated:
02/26/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +227 locations
Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
Register for Updates
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
NCT01424982
Active Not Recruiting
This phase II trial studies the side effects and how well combination chemotherapy and ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ponatinib hydrochloride may stop the growth of canc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Untreated Adult Acute Lymphoblastic Leukemia
Register for Updates
A Novel "Pediatric-Inspired" Regimen with Reduced Myelosuppressive Drugs for Adults (aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
NCT01920737
Active Not Recruiting
The purpose of the study is to find out whether the combination of chemotherapy drugs that are routinely used in children with ALL, will be safe and effective in treating adult patients with ALL. The standard treatment for adults with ALL consists of many chemotherapy drugs that are given in different combinations and in several steps. In adult ALL there is no standard which drugs to give and how to combine them. Some leukemias have a chromosome abnormality called Philadelphia chromosome (also c... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
02/26/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +3 locations
Conditions: Leukemia
Register for Updates
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
NCT02828358
Completed
This pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement. Drugs used in chemotherapy, such as methotrexate, prednisolone, daunorubicin hydrochloride, cytarabine, dexamethasone, vincristine sulfate, pegaspargase, hydrocortisone sodium succinate, azacitidine, cyclophosphamide, mercaptopurine, leucovorin calcium, and thioguanine work in different ways to stop the growth of cancer cells, e... Read More
Gender:
ALL
Ages:
364 days and below
Trial Updated:
02/26/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +169 locations
Conditions: Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
Register for Updates
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
NCT06019728
Completed
This Phase 4 study will evaluate the safety and tolerability of Fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume. This study aims to generate data to provide the guidance on how infusion rate can be safely increased and minimize the burden of the life-long treatment with Fabrazyme.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
02/24/2025
Locations: UCLA Medical Center Site Number : 1003, Santa Monica, California +4 locations
Conditions: Fabry's Disease
Register for Updates
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
NCT04405167
Active Not Recruiting
This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Multiple Myeloma
Register for Updates
Post-operative Methylprednisolone Taper Course for Orthopedic Surgery
NCT03661645
Enrolling By Invitation
The clinical trial is a prospective randomized control trial of a group of patients undergoing surgical management of common orthopedic pathologies including fractures of the upper extremity and shoulder arthroplasty; arthritis surgeries (ex. carpometacarpal arthroplasty), release of compressive neuropathies (ex. carpal tunnel surgery), tendon procedures (ex. tendon repair), patients undergoing total hip arthroplasty for osteoarthritis of the hip or total knee arthroplasty for osteoarthritis of... Read More
Gender:
ALL
Ages:
Between 18 years and 95 years
Trial Updated:
02/22/2025
Locations: Emory Clinic A, Clifton Road Clinic, Atlanta, Georgia +2 locations
Conditions: Orthopedic Surgeries
Register for Updates